DEVELOPMENT pipeline
Reinvesting our profit to discover new medicines
At Servier, major investment in R&D (Close to 20% of revenue from brand-name medicines) creates a promising pipeline of innovative projects targeting illnesses with significant unmet medical needs. Our pipeline reflects our ambition to concentrate on the quality and potential of R&D projects, half of which have the potential to become “first-in-class” medicines.
In March 2026, it comprised 63 projects, 40 of which in clinical development and 23 research projects.
• Oncology
solid tumors
Ivosidenib/
+ durvalumab + gemcitabine/cisplatine
IDH1
Vorasidenib/
+ temozolomide
IDH1/2
Vorasidenib/
+ pembrolizumab
IDH1/2
S095018
(in association)
TIM3
Non-small Cell Lung Cancer
S095024
(in association)
CD73
Non-small Cell Lung Cancer
S095029
(in association)
NKG2A
Non-small Cell Lung Cancer
S095029
(in association)
NKG2A
hematological malignancies
Ivosidenib/
+ 7+3 (chemotherapy)
IDH1
Ivosidenib /
azacitidine / venetoclax
IDH1
Cemacastagene / Ansegedleucel
(Cema-Cel)*
CD19
Diffuse Large B-Cell Lymphoma
Partner :
Licensed from Cellectis and Sub-Licensed to Allogene*
S243249
MENIN
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
S236220
ND**
Hematological malignancies
S247567
ND**
Hematological malignancies
• Neurology
S247240
Chemical entity
BK channel
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene, leading to a deficiency of the fragile X mental retardation protein (FMRP). This protein is crucial for normal brain development and function. The absence of FMRP disrupts synaptic plasticity, which is essential for learning and memory, resulting in cognitive impairments and behavioral challenges.
Patients with Fragile X syndrome often exhibit a range of symptoms, including intellectual disability, anxiety, and social difficulties. The condition can also manifest itself through physical features such as an elongated face and enlarged ears.
S230815
AntiSense Oligonucleotide
KCNT1
KCNT1-related Developmental and Epileptic Encephalopathy (DEE) are a group of severe neurological disorders characterized by very early-onset seizures and significant developmental delays. KCNT1-DEE is caused by genetic mutations in the KCNT1 gene that disrupt normal brain development and function. The seizures are most often refractory to standard anti-epileptic medication, complicating treatment.
Patients with KCNT1-DEE experience a range of symptoms, including severe cognitive impairments, motor deficits, and behavioral issues. The impact on family dynamics and overall quality of life is profound.
More details about ASO technology
S233107
ND**
Movement disorders are a diverse group of neurological conditions characterized by abnormal movements that significantly impact daily functioning. These disorders are often due to genetic mutations, neurodegenerative processes, or environmental factors affecting the brain’s motor control pathways. Common examples include sustained muscle contractions and abnormal postures, as irregular, rapid movements difficult to control.
Patients with rare movement disorders often face challenges in mobility, communication, and social interactions. The unpredictability of symptoms is often associated with emotional distress and a reduced quality of life.
• Cardiometabolism & Venous diseases
Ivabradine
(new formulation)
Dapagliflozin / Bisoprolol
Bisoprolol / Perindopril / Indapamide / Amlodipine
Perindopril / Indapamide SR / Amlodipine
Bisoprolol / Perindopril / Amlodipine
Dapagliflozin / Gliclazide
(2 formulations)
PCD = Preclinical development phase, 1/2 = Phase 1/2, 2 = Phase 2, 3 = Phase 3, RA = Under regulatory authorities evaluation
* Cema-Cel (ALLO501.A /S 95023) utilize TALEN® gene-editing technology owned by Cellectis. Servier, which has an exclusive license to the anti-CD19 investigational products from Cellectis, has granted Allogene exclusive rights to develop and commercialize Cema-Cel in the U.S., all EU Member States and the United Kingdom. For other candidate products (UCART19v1 and ALLO 501) sub-licensed to Allogene, the ongoing activities are limited to follow up of patients from discontinued trials as per regulatory obligations.
** Not Disclose